We have developed recombinant, replication-incompetent, genomic herpes simplex virus (HSV)-based vectors for gene transfer to the nervous system. In the previous period of funding we have demonstrated that HSV- mediated expression of neurotrophin-3 (NT-3), vascular endothelial growth factor (VEGF), or erythropoietin (EPO) in dorsal root ganglion (DRG) in vivo prevents the progression of neuropathy in mice with streptozotocin (STZ)-induced diabetes. In this competing renewal, we will continue to exploit the natural tropism of HSV vectors for peripheral sensory neurons of the (DRG) to further test the hypothesis that gene transfer of neuroprotective factors to the DRG by means of an HSV-based vector can be used to prevent the progression of diabetic neuropathy, with the ultimate aim of developing a therapy that will be effective for the treatment of human neuropathy.
Four specific aims are described. (1) to determine whether HSV-mediated neuroprotective factor expression prevents the loss of DRG neurons in the streptozocin model of type 1 diabetes;(2) to examine the effect of HSV-mediated delivery of neuroprotective factors in the treatment of diabetic neuropathy in the db/db mouse model of type 2 diabetes;(3) to construct a vector with a regulatable switch to control transgene expression safely;and, (4) to test the effect of intermittent regulated protective factor expression on the progression of diabetic neuropathy in the STZ-diabetic and db/db mouse. Project Narrative Relevance to Public Health: Neuropathy is an important and often disabling complication of both type 1 and type 2 diabetes mellitus, and there are no currently available treatments that are effective in preventing the progression of the complication. These studies are designed to develop novel agents that could be used to treat the disease effectively.
|Wu, Z; Wang, S; Wu, I et al. (2015) Activation of TLR-4 to produce tumour necrosis factor-Î± in neuropathic pain caused by paclitaxel. Eur J Pain 19:889-98|
|Ortmann, Kathryn L Maier; Chattopadhyay, Munmun (2014) Decrease in neuroimmune activation by HSV-mediated gene transfer of TNFÎ± soluble receptor alleviates pain in rats with diabetic neuropathy. Brain Behav Immun 41:144-51|
|Murthy, Rachana; Kim, Jeeyong; Sun, Xiankui et al. (2013) Post-transcriptional regulation of GABAB receptor and GIRK1 channels by Nogo receptor 1. Mol Brain 6:30|
|Chattopadhyay, Munmun (2013) Targeted delivery of growth factors by HSV-mediated gene transfer for peripheral neuropathy. Curr Gene Ther 13:315-21|
|Wu, Zetang; Wang, Shiyong; Gruber, Sandy et al. (2013) Full-length membrane-bound tumor necrosis factor-Î± acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons. Pain 154:1778-82|
|Sun, Xiankui; Zhou, Zhigang; Fink, David J et al. (2013) HspB1 silences translation of PDZ-RhoGEF by enhancing miR-20a and miR-128 expression to promote neurite extension. Mol Cell Neurosci 57:111-9|
|Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277-91|
|Wang, S; Wu, Z; Chiang, P et al. (2012) Vector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury. Gene Ther 19:907-14|
|Sun, J; Liu, S; Mata, M et al. (2012) Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther 19:101-8|
|Lau, Darryl; Harte, Steven E; Morrow, Thomas J et al. (2012) Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury. Neurorehabil Neural Repair 26:889-97|
Showing the most recent 10 out of 48 publications